Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.31−0.40 (-3.73%)
Close on Nov 18, 2026Market cap $630.32MP/E –Yield –
Janux Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Janux Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $24.00M, up 5367.0% year over year. For fiscal 2025 it was $10.00M, down 5.6% from the year before. The highest annual figure on record is $10.59M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.00M | -5.6% |
| FY2024 | Dec 31, 2024 | $10.59M | +31.0% |
| FY2023 | Dec 31, 2023 | $8.08M | -6.1% |
| FY2022 | Dec 31, 2022 | $8.61M | +136.8% |
| FY2021 | Dec 31, 2021 | $3.64M | – |
| FY2020 | Dec 31, 2020 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.27M | – |
| Q1 FY2026 | Mar 31, 2026 | $3.73M | – |
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $10.00M | +2177.9% |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $439.00K | -82.6% |
| Q2 FY2024 | Jun 30, 2024 | $8.90M | +741.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.25M | -38.9% |
| Q4 FY2023 | Dec 31, 2023 | $2.46M | -13.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.52M | +38.8% |
| Q2 FY2023 | Jun 30, 2023 | $1.06M | -55.3% |
| Q1 FY2023 | Mar 31, 2023 | $2.05M | +28.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.85M | +76.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.81M | +56.4% |
| Q2 FY2022 | Jun 30, 2022 | $2.37M | +390.7% |
| Q1 FY2022 | Mar 31, 2022 | $1.59M | +318.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.62M | – |
| Q3 FY2021 | Sep 30, 2021 | $1.16M | – |
| Q2 FY2021 | Jun 30, 2021 | $482.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $380.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
See a number that looks wrong?